- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03129529
Comparing the Effect of Focused and Radial Extracorporeal Shock Waves on Post-stroke Hypertonia
April 25, 2017 updated by: Gwo-Chi Hu,PHD, Mackay Memorial Hospital
The main purpose of this study is to compare treatment efficacy of focused and radial extracorporeal shock waves on spasticity in chronic stroke patient
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective and double-blinded randomized control trial.
Thirty-two stroke patients with spastic equinus were randomly assigned to receive three sessions of either focused shockwave therapy or radial shockwave therapy at 1-week intervals.
The intensities that were used during FSWT (0.1 mJ/mm2) and RSWT (2 bar) were comparable.
Patients were evaluated at baseline and at 1, 4, 8 weeks after the final shockwave treatment.
The primary outcome measure was modified Ashworth scale (MAS) score.
Secondary outcome measures were Tardieu scale, ankle passive range of motion, plantar contact area during gait, and gait speed.
A linear mixed model with repeated measures was used to compare each outcome measure between the two groups.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 104
- Mackay Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- aged greater than 18 years old;
- at least 6 months since onset of last stroke;
- triceps surae muscle tone graded at least 1+ on the Modified Ashworth Scale (MAS) score;
- ability to walk alone with/without orthosis.
Exclusion Criteria:
- Exclusion criteria included fixed ankle joint contracture, previous treatment of the affected leg with neurolytic or surgical procedures, concomitant progressive central nervous system diseases, and skin breakdown, vascular disease in the affected leg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: focused shock wave
Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval.
During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.
The intensities of FSWT were 0.10 mJ/mm2.
|
The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
|
|
Experimental: radial shock wave
Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval.
During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
|
The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline of spasticity on 1st, 4th, 8th weeks after treatment.
Time Frame: 1, 4, 8 week
|
Using the modyfied Ashworth Scale to measure the spasticity before treatment and multiple time frame after treatment.
|
1, 4, 8 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline of range of motion on 1st, 4th, 8th weeks after treatment.
Time Frame: 1, 4, 8 week
|
Using the digital goniometer to measure the passive range of motion before treatment and multiple time frame after treatment.
|
1, 4, 8 week
|
|
Change from baseline of modified Tardieu scale on 1st, 4th, 8th weeks after treatment.
Time Frame: 1, 4, 8 week
|
Using the modified Tardieu scale (MTS) to measure the spasticity before treatment and multiple time frame after treatment.
|
1, 4, 8 week
|
|
Change from baseline of foot contact area on 1st, 4th, 8th weeks after treatment.
Time Frame: 1, 4, 8 week
|
Using the baropodometric measurement to measure the foot contact area before treatment and multiple time frame after treatment.
|
1, 4, 8 week
|
|
Change from baseline of gait speed on 8th weeks after treatment.
Time Frame: 8 week
|
Using the 10 meters walking test to measure the gait speed before treatment and after treatment.
|
8 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
April 20, 2017
First Submitted That Met QC Criteria
April 25, 2017
First Posted (Actual)
April 26, 2017
Study Record Updates
Last Update Posted (Actual)
April 26, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15MMHIS194e
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spasticity
-
Ospedale Generale Di Zona Moriggia-PelasciniSuspended
-
IRCCS Sacro Cuore Don Calabria di NegrarRecruiting
-
Pacira Pharmaceuticals, IncCompletedUpper Limb SpasticityUnited States
-
IpsenCompletedLower Limb SpasticityUnited States
-
IpsenCompletedUpper Limb SpasticityTaiwan, United States, Germany, Australia, Hong Kong, Philippines, France, Russian Federation, Italy, Portugal, Brazil, Austria, Mexico, Poland
-
Merz Pharmaceuticals GmbHCompletedUpper Limb SpasticityFrance, Spain, Switzerland, United Kingdom, Italy, Austria, Germany, Portugal
-
Vancouver Island Health AuthorityRecruiting
-
Universitatea de Medicina si Farmacie Iuliu HatieganuRecruiting
-
Nantes University HospitalCompiègne University of TechnologyCompleted
Clinical Trials on Focused shock wave
-
University Hospital St. PoltenNot yet recruiting
-
Cairo UniversityRecruitingCervical RadiculopathyEgypt
-
Medical University of ViennaUnknown
-
National Taiwan University HospitalRecruitingStroke | Muscle SpasticityTaiwan
-
National Taiwan University HospitalRecruitingStroke | Spasticity, MuscleTaiwan
-
Foundation IRCCS San Matteo HospitalCompleted
-
Peking University Third HospitalRecruitingRotator Cuff TearChina
-
Cheng-Hsin General HospitalWithdrawnTrigger Finger | Stenosing Tenosynovitis
-
Fundación Garcia CugatCompletedEffectiveness of Shockwave Treatment for Proximal Fifth Metatarsal Stress Fracture in Soccer PlayersStress Fracture MetatarsalSpain
-
Dr. Johannes FleckensteinCompletedMusculoskeletal Pain | Athletic InjuriesGermany